好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sentiment Analysis of Digital Conversations Related to Myasthenia Gravis by Race/Ethnicity
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (11:45 AM-12:45 PM)
11-019

To describe sentiments, barriers and drivers related to myasthenia gravis (MG) through analyzing conversations by race/ethnicity.

MG is a rare, autoantibody neuromuscular disease characterized by muscle weakness and fatigue, which imposes profound patient burden. Digital conversations can provide unprompted insights into perceptions and highlight areas of greatest concern to MG patients. There is a lack of data focusing on race/ethnicity.

US-based public domain patient conversations focusing on MG and posted within topical sites, message boards, social networks, and blogs from August 2022-23 were mined.  Content contributors were patients self-identified as White, Black, Hispanic, or Asian within the conversations or on public profiles. Advanced search techniques and artificial intelligence powered algorithms were used to extract/organize data by topics. Natural language processing was conducted to identify sentiments, mindsets, and drivers/barriers towards treatment.

13,163 conversations were extracted and segmented by patient race/ethnicity.  Among 1,678 conversations by Black patients, 67% were negative led by “misdiagnosis problems” (23%) and "impact on life (23%). “Uncertain” mindsets were more frequent among Black and Hispanics than White and Asian patients (47% and 55% vs. 39% and 40%). Frequent themes related to “barriers to treatment” were lack of efficacy and side effects for all groups. "Level of relief", "duration", and "symptom relief" were the most frequent themes within the efficacy category for all groups. Cost/insurance was a more dominant theme for Black and Hispanic than Asian and White patients (15% and 18% vs. 4% and 5%).

Conversations by race/ethnicity that may indicate relevant differences in the experiences of people living with MG. Black and Hispanic patients more frequently discuss misdiagnosis, which is often a challenge in the MG patient journey. Additionally, conversations highlighting cost/insurance issues may point to health disparities for persons of color. This data informs management strategies personalized to individual patients’ needs and priorities.

Authors/Disclosures
Louis Jackson, PharmD (Janssen)
PRESENTER
Dr. Jackson has received personal compensation for serving as an employee of Johnson and Johnson.
Nizar Souayah, MD, FAAN (NJMS) Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.
Caroline Brethenoux (CulturIntel) No disclosure on file
Alyssa DeLuca (Human Dot Plus) No disclosure on file
Jacqueline Pesa (Janssen) Jacqueline Pesa has received personal compensation for serving as an employee of Johnson and Johnson.
Zia U. Choudhry, MD, PhD (JOHNSON AND JOHNSON) Dr. Chaudhry has received personal compensation for serving as an employee of Johnson & Johnson. Dr. Chaudhry has received personal compensation for serving as an employee of Takeda Pharmaceuticals.
Patrick Furey (Culturintel) No disclosure on file
Rosario Alvarez (Human.+) No disclosure on file
Laura Gonzalez Quijano (Human Dot Plus) No disclosure on file
Alex Lorenzo No disclosure on file
Ashley E. Anderson, MD (Houston Methodist - Department of Neurology) Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/Johnson&Johnson. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen.